Published online before print January 18, 2007, doi: 10.1161/01.RES.0000257913.42552.23
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 American Heart Association, Inc.
Integrative Physiology |
MicroRNAs Play an Essential Role in the Development of Cardiac Hypertrophy
From the Cardiovascular Research Institute, Department of Cell Biology and Molecular Medicine, University of Medicine and Dentistry of New Jersey, Newark.
Correspondence to Maha Abdellatif, Cardiovascular Research Institute, Department of Cell Biology and Molecular Medicine, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103. E-mail abdellma{at}umdnj.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
MicroRNAs are naturally existing, small, noncoding RNA molecules that downregulate posttranscriptional gene expression. Their expression pattern and function in the heart remain unknown. Here we report an array of microRNAs that are differentially and temporally regulated during cardiac hypertrophy. Significantly, the muscle-specific microRNA-1 (miR-1) was singularly downregulated as early as day 1 (0.56±0.036), persisting through day 7 (0.29±0.14), after aortic constriction–induced hypertrophy in a mouse model. Overexpression experiments showed that miR-1 inhibited its in silico–predicted, growth-related targets, including Ras GTPase–activating protein (RasGAP), cyclin-dependent kinase 9 (Cdk9), fibronectin, and Ras homolog enriched in brain (Rheb), in addition to protein synthesis and cell size. Thus, we propose that microRNAs play an essential regulatory role in the development of cardiac hypertrophy, wherein downregulation of miR-1 is necessary for the relief of growth-related target genes from its repressive influence and induction of hypertrophy.
Key Words: microRNA • cardiac hypertrophy • microarray • miR-1
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
With the discovery of microRNA, we are compelled to revise our understanding of the mechanisms regulating normal and pathological cellular functions. These fundamental regulators are noncoding RNA molecules (
21 nucleotides [nt]) that silence genes through posttranscriptional regulation. The first microRNA was discovered in 1993, when Lee et al found that lin-4, which downregulates the levels of lin-14 during the development of Caenorhabditis elegans, expresses a small noncoding 22-nt RNA.1 Not until 7 years later did Reinhart et al report the discovery of the second microRNA, let-7, which induces downregulation of lin-41 protein.2 This was shortly followed by identification of a multitude of human and fly microRNAs, some of which are highly conserved, such as let-7,3 thus reflecting their essentiality. Interestingly, it was found that in each of the heart, brain, and liver, there is a distinct tissue-specific microRNA that predominates, which led to the idea that microRNAs must be involved in tissue differentiation.4 There are collectively more than 4000 microRNA sequences existing in a wide range of species. These are annotated and catalogued in a searchable Web-based data registry by Welcome Trust Sanger Institute.5,6
Identification of the genomic locations of microRNAs revealed that they exist within introns or exons of protein-coding mRNA or noncoding RNA.7 Evidence suggests that microRNAs are expressed as an integral part of their host transcript.8 This transcript, or its processed products, is considered the primary microRNA and is cleaved in the nucleus by the enzyme Drosha, yielding a pre-microRNA, which is a short stem-loop structure 70 nt.9,10 Pre-microRNA is then exported to the cytoplasm for further processing by Dicer into the mature microRNA sequence. This is where microRNA converges onto the same pathway that is known to process small interfering RNA.11 This includes incorporation of the single stranded microRNA into the RNA-induced silencing complex (RISC). Mature microRNA binds to the 3' untranslated region of its target mRNA through exact complementarity, strictly, with its 5-prime 7 to 8 nt, and partial complementarity with rest of the sequence.12 Using this criterion, computational predictions of microRNA targets reveal that a single microRNA has the potential to inhibit up to 200 mRNAs. Depending on the overall degree of complementarity, microRNA will either inhibit translation or induce degradation of its target. The previous results showed that lin-4 microRNA downregulated lin-14 protein but not mRNA, which suggested that the partial complementarity between microRNA and its target inhibited protein translation,1 but the mechanism is unknown.
Because of their major roles as oncogenes and tumor suppressors, a group of microRNAs have been dubbed "oncomirs."13 In cancer, the discovery of microRNA is offering answers to previously unresolved questions. For example, after years of futile attempts to identify the gene(s) in the deleted 13q14 region that participate in the pathogenesis of chronic lymphocytic leukemia, Calin et al discovered that miR-15 and miR-16 are located within this sequence and that both are downregulated in 68% of cases.14 These microRNA molecules are now considered tumor suppressors, among their targets being Bcl2, the level of which reciprocally correlates with that of miR-15/16 in chronic lymphocytic leukemia.15 Calin et al have then gone on to show that 52.5% of microRNAs are located in fragile genomic sites that are frequently deleted in cancer.16 In contrast, overexpression of microRNA is also associated with cancer. For example, miR-155 is upregulated in B-cell lymphoma.17 Notably, tissue-specific overexpression of miR-155 in a transgenic mouse model proved it sufficient for induction of lymphoblastic leukemia.18 Overall, unique microRNA expression profiles have been detected in chronic lymphocytic leukemia,19 breast,20 and lung cancers,21 which could aid in the diagnosis and prognosis of cancer.21 Lu et al showed that classification of poorly differentiated tumors was possible with microRNA, but not mRNA, expression profiling.22 Thus, microRNAs provide us with a more accurate diagnostic tool.
miR-1 was identified as a muscle-specific microRNA.4 Its expression is detected as early as embryonic day (E) 8.5 in the mouse heart and increases with the progression of differentiation.23 When overexpressed with a ß-myosin heavy chain (MHC) promoter in a transgenic mouse model, miR-1 inhibited myocyte proliferation and cardiac development. In Drosophila, a DmiR-1KO mutant dies as a small second in-star larvae, 2 to 7 days after hatching, from apparent paralysis.24 On the other hand, the first larvae stage is normal; it is only after feeding that paralysis and death are triggered. From this, it was concluded that miR-1 is not involved in muscle formation but in postmitotic muscle growth and function.
Although microRNA studies predominate in the cancer field, little is known about their expression patterns or role in other diseases, especially cardiovascular disorders. Pressure-overload cardiac hypertrophy is a multigene disease, which involves a global change in the gene expression profile, but the mechanism for this is unknown. In this study, we addressed whether an underlying change in the microRNA expression profile plays a hand in regulating the gene expression pattern characterizing cardiac hypertrophy. Our results point to a single muscle-specific microRNA molecule, miR-1, that is downregulated at the onset of pressure overload on the heart. An outcome that appears sufficient for inducing the gene expression changes underling cardiac hypertrophy and initiating growth.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Transverse Aortic Constriction
C57 BL/6 mice were anesthetized (IP) with a mixture of ketamine (0.066 mg/g), xylazine (0.013 mg/g), and acepromazine (0.002 mg/g). The animals were then ventilated via tracheal intubation connected to a rodent ventilator (Harvard Apparatus) with a tidal volume of 0.2 mL and a respiratory rate of 110 breaths per minute. The left chest was opened at the second intercostal space and the thymus glands were superiorly reflected. The transverse thoracic aorta between the innominate artery and left common carotid artery was dissected and a 7-0 nylon suture tied around the aorta against a 28-gauge needle. A control group underwent a sham operation involving thoracotomy and aortic dissection without constricting the aorta.
MicroRNA Microarray
Total RNA was extracted form the hearts of the mice that have undergone transverse aortic constriction or sham operation, using TRIzol reagent according to the protocol of the manufacturer (Invitrogen). Ten micrograms of RNA were sent to L.C. Sciences for microRNA microarray. Samples were enriched for small RNA, after which each pair of sham and transverse aortic constriction (TAC) samples were labeled with Cys3 and Cys5 fluorescent dyes and hybridized to a single Atactic µParaFlo microfluidics chip that held all 334 mature rodent microRNA probes identified to date, as well as perfectly matched and mismatched probes for quality control. Each microRNA probe is represented 9x on the microarray. Among the control probes, PUC2PM-20B and PUC2MM-20B are the perfect match and single-based match detection probes, respectively, of a 20-mer RNA positive control sequence that is spiked into the RNA samples before labeling. One may assess assay stringency from the intensity ratio of PUC2PM-20B and PUC2MM-20B, which is normally larger than 30. After signal amplification, the background was subtracted and normalized using LOWESS (locally weighted regression) method. For a transcript to be listed as detectable, it must meet the following criteria: signal intensity higher than 3x (background SD), spot coefficient of variation<0.5 (coefficient of variation=SD/signal intensity), and signals from at least 50% of the repeating probes above detection level.
The array output was received in Excel spreadsheets as lists of raw data and also as "simple detectable" data, which were the average of 9 signal values for each microRNA on the array. For each TAC/sham triplicate set at each time point analyzed, we calculate the significant differences (probability values) between TAC and sham for a given detectable microRNA signal. Those with P
0.05 are analyzed using gene hierarchical clustering of the log2 value of each TAC/sham pair of signals and displayed in a heatmap. Clustering was performed using Cluster 3.0 (created by Michiel de Hoon, Seiya Imoto, and Satoru Miyano, University of Tokyo, Human Genome Center) and viewed in a heatmap using Java TreeView 1.0.13 software.
Northern Blot
Total RNA (25 µg), extracted using TRIzol reagent according to the protocol of the manufacturer (Invitrogen), was separated on 1% agarose gel with 3% formaldehyde and 10% 10x 4-morpholinepropanesulfonic acid. The RNA was transferred to an uncharged nylon membrane and UV cross-linked. The membrane was prehybridized at 42°C for 2 hours with 1 mL/cm2 QuikHyb Hybridization solution (Stratagene). DNA oligonucleotides, complementary to the mature microRNAs, were obtained from Integrated DNA technologies. The probes were 5'-end labeled with Redivue adenosine 5'-[
-32P] triphosphate, triethylammonium salt (Amersham Biosciences) using microRNA probe and marker kit (Ambion) and used for hybridization (1x105/cm2). The blot was hybridized overnight and then washed with 2x sodium chloride sodium citrate buffer/0.1% sodium dodecyl sulfate (SDS) and exposed to X-ray film for 24 hours at –80°C. Blots were stripped using 0.5% SDS for 1 hour at 60°C and reprobed after prehybridization.
Culturing Cardiac Myocyte and Adenovirus Infection
Cardiac myocytes were prepared as previously described.25 Briefly, hearts were isolated from 1- to 2-day old Sprague–Dawley rats as approved by the institutional animal care and use committee. After dissociation, the cells were subjected to Percoll gradient centrifugation, followed by differential preplating to enrich for cardiac myocytes and deplete nonmyocytes. Cells were then plated in DMEM/Ham F12 with 10% FCS, at a density of 0.5 to 1x105 cells/cm2. Twenty-four hours after plating, serum was removed and the cells were infected with recombinant adenoviruses at a multiplicity of infection (moi) of 10 to 20 particles per cell.
Construction of Adenoviruses
Recombinant adenoviruses were constructed, propagated, and tittered as previously described by Graham and Prevec.26 Briefly, pBHGlox
E1,3Cre (Microbix), including the E1 adenoviral genome, was cotransfected with the pDC shuttle vector containing the gene of interest, into 293 cells using Lipofectamine (Invitrogen). Through homologous recombination, the test genes integrate into the E1-deleted adenoviral genome. The viruses were propagated on 293 cells and purified using CsCl2 banding, followed by dialysis against 20 mmol/L Tris buffered saline with 2% glycerol. Tittering was performed on 293 cells overlaid with DMEM plus 5% equine serum and 0.5% agarose.
Cell Fractionation and Western Blotting
Cells were fractionated into cytosol, membranes, nuclei, and cytoskeleton, using a Subcellular ProteoExtract kit (Calbiochem), according to the protocol of the manufacturer. The protein (5 to 10 µg) was analyzed on a 4% to 20% gradient SDS-PAGE (Criterion gels, Bio-Rad).
The antibodies used include: anti-Rheb (ProSci Incorporated), anti-fibronectin (BD Transduction), anti-Cdk9 (Santa Cruz Biotechnology), anti-RasGAP and anti–phospho-ribosomal protein S6 (S235) (Upstate Biotechnology), anti–
-sarcomeric actin (Biomeda Corp), anti-MHC (Hybridoma Bank, University of Iowa).
Monitoring Proteins Synthesis
Protein was monitored by the incorporation of [3H]-leucine into total cellular protein and normalized to the DNA content, as previously described.27
Immunocytochemistry
Cells were fixed in 3% paraformaldehyde plus 0.3% Triton X-100 in PBS at 25°C for 5 minutes followed by 3% paraformaldehyde in PBS at 25°C for 20 minutes. They were then incubated with anti-MHC (MF-20) at 1:100 in Tris-buffered saline with 1% BSA. After an overnight incubation, they were washed and the secondary antibody Alexa-598 plus phalloidin–Alex488 (Molecular Probes) were added to the cells. After washing, the slides were mounted using Prolong Gold Antifade with 4',6-diamidino-2-phenylindole (DAPI) (Molecular Probes).
Measurement of Imaged Cell Surface Area
Cells were imaged at x40 magnification. The relative surface area of an image a cell was calculated from the number of pixels outlined using "lasso" tool in Adobe Photoshop. Twenty cells were scored for each condition.
Statistics
Significant differences (probability values) between the experimental groups were calculated using 1-way, unpaired Student’s t test. All experiments were repeated 3 times and presented as average±SE of the mean.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
To identify microRNAs that are differentially expressed during cardiac hypertrophy, we used comprehensive, rodent-specific microRNA microarray analysis of RNA from the hearts of mice subjected to TAC or a sham operation. Hearts were isolated from mice 1, 7, and 14 day post-TAC or sham operation (n=3, each). Total RNA was extracted, enriched for small RNA, and analyzed by microarrays of mature rodent microRNA. TAC and sham samples were paired and analyzed on single arrays using dual labeling. From the microarray normalized values, the significant differences (probability values) between TAC and sham for a given detectable microRNA signal at each time point was calculated. Those with P
0.05 were analyzed using hierarchical clustering of the log2 value of each TAC/sham pair of signals and displayed in a heatmap (Figure 1). The figure reflects the extent of temporal changes in microRNA levels during the progression of TAC-induced hypertrophy. Those changes equally represent microRNAs that are upregulated (red), as well as downregulated (green). Also, from examining the heatmap, one can classify microRNAs into 3 subgroups (Table): (1) microRNA with expression levels that change preceding an increase in heart/body weight and persist (1 to 14 days post-TAC); (2) microRNA changes that correlate with the increase in heart/body weight (7 to 14 days post-TAC); and (3) microRNA changes that are only observed during the later stage of hypertrophy (14 days post-TAC).
|
|
Figure 2 shows both the relative signal intensity of the microRNA microarray readout (1 to 65 535), which reveals the abundance of each microRNA in the heart. As early as 24 hours post-TAC, with no change in heart/body weight, there were significant (P0.05), albeit small, changes in the expression of 5 microRNAs (Figure 2a). Notably, microRNA-1 (miR-1) is a skeletal and cardiac muscle-specific microRNA necessary for postmitotic muscle growth and differentiation.23,24 As expected, its signal intensity was the highest on the microarray. Most interestingly, miR-1 was downregulated at 1 day post-TAC (0.74±0.19). Of the 5 detected at 1 day, the decrease in miR-1 persisted and was accentuated in 7 days post-TAC hearts (0.62±0.05; Figure 2b). The hearts at that time showed 23±6% (P=<0.01, sham versus TAC) increase in heart/body weight. Overall, at that time point, 11 microRNAs were downregulated and 16 upregulated, 22 of which persisted up to day 14 post-TAC. Of those mir-199a, -199a*, -199b, -21, -214 showed the greatest changes (>2-fold upregulation). Total, after 14 days, 26 microRNAs were downregulated and 25 were upregulated (Figure 2c). At this time, the heart/body weights were increased by 33±5% (P=<0.01, sham versus TAC), 1 week preceding heart failure in this model. Interestingly, miR-1 appeared to be returning back to normal levels (0.83±0.04). In contrast, miR-133a/b also a muscle-specific microRNA, was highly expressed in the heart but remained unchanged up to 14 days after TAC. We also noted that miR-206, which only differs from miR-1 by 3 of 21 nt, was undetectable on any of the microarrays, thus, reflecting the high specificity of these results.
|
To confirm the microarray data for miR-1 and miR-21, we performed Northern blot analysis on total RNA extracted from the hearts of 1-, 7-, and 14-day TAC or sham operated mice that was used for the microarray analysis (Figure 3a). After quantitation of the signal intensity and normalization to U6, we found that the results correlated well with the microarray data, with even greater differences between the TAC and sham signals (Figure 3b). In agreement, miR-1 was also 55% lower in neonatal myocytes cultured in the presence of growth-promoting 10% FBS versus growth-inhibited conditions (Figure 3c).
|
Because miR-1 emerges as 1 of the earliest microRNA to be regulated and its downregulation persists through the initial phase of cardiac growth, we questioned whether it plays a role in the induction of hypertrophy. To address this, we constructed an adenoviral vector harboring the premature stem-loop sequence of mouse miR-1-2 (Figure 4). MicroRNA stem-loop is usually contained within a larger primary transcript, ranging from a few hundred to thousands of base pairs, that is processed by Drosha. Therefore, it was unclear whether it was best to express this construct from a polymerase II (cytomegalovirus [CMV])- or a polymerase III (U6)-dependent promoter; therefore, both were engineered. The latter has better defined start and stop sites that would allow the expression of the stem-loop with little flanking vector sequences. On the other hand, the CMV promoter would encompass any 5' and 3' untranslated vector sequences, including 200 bp of SV40 polyA signal sequence provided by the cloning plasmid for construction of the adenovirus. To determine the expression of miR-1 from these viral constructs, we delivered them to cultured neonatal cardiac myocytes and after 24 hours, analyzed them by Northern blotting for miR-1. Overexpression of miR-1 using the CMV promoter resulted in accumulation of the primary transcript, the stem-loop (72 nt), and the mature miR-1 (21 nt), whereas the control cells showed the mature sequence (Figure 4b). Limited processing capacity might reflect limiting processing factors. The mature, viral-expressed miR-1 was 2.5x higher than the endogenous levels. On the other hand, there was modest increase in miR-1 from the U6 promoter (1.3-fold) and, as noted, no accumulation of primary transcript. Therefore, it is feasible to express stem-loop premature microRNA from either a CMV or a U6 promoter, independent of the context, in cardiac cells, where they are successfully processed into mature sequences, the former, though, resulting in a more robust expression.
|
As shown above, miR-1 is decreased in the early stages of hypertrophy. Thus, the prediction is that miR-1 represses genes that are necessary for induction of cardiac hypertrophy. Sanger Institute, in silico–predicted targets of miR-1 include Ras GTPase–activating protein (RasGAP) (P=0.0002), cyclin-dependent kinase 9 (Cdk9) (P=0.0001), Ras homolog enriched in brain (Rheb) (P=0.006), and fibronectin (P=0.00013). Our previous reports have shown that both RasGAP and Cdk9 are upregulated and necessary for the development of cardiac hypertrophy.28,29 Rheb is an upstream activator of the mammalian target of rapamycin (mTOR)/S6 kinase pathway involved in protein synthesis and cell growth.30,31 Thus, an increase in those proteins, facilitated by reduction of miR-1, may be expected to support hypertrophy and vice versa.
To test this hypothesis, we overexpressed miR-1 in serum-starved neonatal cultured myocytes, before stimulation with serum-enriched medium, which is a robust hypertrophic stimulus. The assumption was that constitutive overexpression of exogenous miR-1 will counteract the reduction of endogenous miR-1 that is associated with serum-induced hypertrophy. Our results show that CMV.miR-1 effectively inhibited serum-induced RasGAP, Cdk9, fibronectin, and Rheb and partially phosphorylation of the downstream effector ribosomal S6 (Figure 5a) in a dose-dependent manner. In addition, the increase in sarcomeric -actin and MHC (localized to the cytoskeletal fractions) that is associated with hypertrophic growth was also inhibited, whereas cytosolic actin monomer remained unchanged. At a moi of 10, the miR-1 virus inhibited serum-stimulated expression of all aforementioned genes by >90%, except for cytosolic and membranous pS6, which was reduced by 40%, thus, reflecting the intactness of other upstream pathways regulating S6. In contrast, this dose of miR-1 did not perturb basal levels. At a moi of 15, though, basal levels were greatly reduced to below detectable levels in some cases. It should be mentioned here that markers of apoptosis, including phospho-H2Ax and -H2B, were undetectable at the miR-1 doses used in this experiment (data not shown). RasGAP, histone H2A, and MHC expression patterns validate cytosolic and membranous, nuclear, and cytoskeletal fractions, respectively. Thus, the results suggested that miR-1 inhibits hypertrophic growth. This was verified by monitoring protein synthesis in cultured myocytes using [3H]-leucine (Figure 5b). Myocytes treated with serum-enriched medium exhibited a 16% increase in [3H]-leucine incorporation normalized to DNA content versus myocytes cultured in serum-free medium, over a period of 24 hours. In the presence of excess miR-1, basal, as well as serum-stimulated [3H]-leucine incorporation was inhibited. This is plausibly attributable to the inhibition of basal and serum-stimulated levels of growth-related proteins, such as RasGAP, Cdk9, and Rheb, seen in Figure 5a. This was accompanied by 91.5±7% and 95±3% inhibition of cell spreading induced by FBS or endothelin (P<0.001, FBS or ET-1 versus FBS or ET-1 in the presence of miR-1), respectively, as well as inhibition of the increase in the hypertrophic marker atrial natriuretic factor in myocytes cultured on uncoated glass surface (Figure 5c).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The molecular mechanism underlying cardiac hypertrophy involves a change in the gene expression profile that recapitulates the neonatal growth phenotype.32 This mostly includes the upregulation of translation-, transcription-, and survival-related genes.32 Because a single microRNA has the potential to target and inhibit up to 200 genes at a time, we hypothesized that they play a role in defining the expression profile that characterizes hypertrophy. Indeed our results reveal an array of more than 50 microRNAs with expression that progressively changes during development of pressure-overload cardiac hypertrophy. We have identified miR-1 as among the earliest microRNAs downregulated during hypertrophy. It has highly relevant in silico targets that included RasGAP, Cdk9, Rheb, and fibronectin, which we confirmed to be valid in vivo targets as well. miR-1 was previously identified as a muscle-specific microRNA.4 It has been shown that serum response factor regulates its expression in the mouse heart as it increases gradually in parallel with myocyte differentiation23 and where its levels are highest in the adult versus embryonic or neonatal hearts. In other words, relatively lower levels of miR-1 are associated with the neonatal hypertrophic growth of the heart. Accordingly, we propose that miR-1 is downregulated on induction of hypertrophy, plausibly through an serum response factor–dependent mechanism. This downregulation is required for the release of its growth-related targets, including RasGAP, Cdk9, fibronectin, and Rheb, from its inhibitory influence.
Another interesting microRNA includes miR-21, which is 2x upregulated by day 7 post-TAC, gradually increasing to reach 8x greater than basal by day 14. Distinctively, miR-21 has been reported to be upregulated in a multitude of human cancers,33 in which it appears to play an antiapoptotic role.34,35 Some of its relevant, Sanger Institute, in silico–predicted targets include Fas ligand and transforming growth factor-ß receptor, both of which await to be confirmed in vivo. Cardiac work overload is a stress condition that induces a degree of apoptosis, which correlates with the extent and duration of the imposed load. During the early stages, the heart counteracts this burden by compensatory mechanisms that involve cellular hypertrophy and activation of antiapoptotic pathways. We predict that upregulation miR-21 in the heart provides a powerful antiapoptotic mechanism, because of its capacity to simultaneously regulate multiple proapoptotic genes.
Functional studies of mammalian microRNAs have been lagging, possibly because of the slow development of the appropriate tools. Antisense, nonhydrolyzable microRNAs have recently been used as effective inhibitors of microRNAs. On the other hand, in vivo knockout is hampered by the fact that microRNAs may have more than 1 copy that may be differentially expressed and some contained within the mRNA of other genes. Studies in cardiac myocytes are further complicated by their poor capacity for transfection (3% to 10%). For that purpose, we emphasize here the successful use of recombinant adenovirus to transfer microRNA to cardiac myocytes with high efficiency by using the stem-loop pre-microRNA under the control of the CMV promoter. This also shows that the pre-microRNA is the minimum sequencing required for expression of mature microRNA and is independent of the context, circumventing the need for genomic cloning.
In brief, the deregulation of microRNA is proving to be an underlying cause of cellular dysfunction and disease. This is especially true in many forms of cancer, where these regulatory molecules have provided better prognostic and diagnostic tools, as well as new therapeutic targets. Our data suggest that microRNAs play an essential role during cardiac hypertrophy with a potential for similarly providing us with new diagnostic, prognostic and therapeutic targets for cardiovascular disorders.
|
Acknowledgments |
|---|
We thank Dr S. Vatner, Chairman of the Department of Cell Biology and Molecular Medicine (University of Medicine and Dentistry of New Jersey, Newark), for advice and support.
Sources of Funding
This study is supported in part by the NIH grants 2R01 HL057970-06 and 1 R01 HL081381-01A1 (to M.A.).
Disclosures
None.
|
Footnotes |
|---|
Original received October 18, 2006; revision received December 19, 2006; accepted January 4, 2007.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75: 843–854.[CrossRef][Medline] [Order article via Infotrieve]
2. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000; 403: 901–906.[CrossRef][Medline] [Order article via Infotrieve]
3. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001; 294: 853–858.
4. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002; 12: 735–739.[CrossRef][Medline] [Order article via Infotrieve]
5. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006; 34: D140–D144.
6. Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res. 2004; 32: D109–D111.
7. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004; 14: 1902–1910.
8. Baskerville S, Bartel DP. Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA. 2005; 11: 241–247.
9. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 2002; 21: 4663–4670.[CrossRef][Medline] [Order article via Infotrieve]
10. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003; 425: 415–419.[CrossRef][Medline] [Order article via Infotrieve]
11. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281–297.[CrossRef][Medline] [Order article via Infotrieve]
12. Lai EC. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet. 2002; 30: 363–364.[CrossRef][Medline] [Order article via Infotrieve]
13. Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6: 259–269.[CrossRef][Medline] [Order article via Infotrieve]
14. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002; 99: 15524–15529.
15. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102: 13944–13949.
16. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101: 2999–3004.
17. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005; 102: 3627–3632.
18. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, Croce CM. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A. 2006; 103: 7024–7029.
19. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell’Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M, Croce CM. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A. 2004; 101: 11755–11760.
20. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65: 7065–7070.
21. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9: 189–198.[CrossRef][Medline] [Order article via Infotrieve]
22. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature. 2005; 435: 834–838.[CrossRef][Medline] [Order article via Infotrieve]
23. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature. 2005; 436: 214–220.[CrossRef][Medline] [Order article via Infotrieve]
24. Sokol NS, Ambros V. Mesodermally expressed Drosophila microRNA-1 is regulated by Twist and is required in muscles during larval growth. Genes Dev. 2005; 19: 2343–2354.
25. Abdellatif M, MacLellan WR, Schneider MD. p21 Ras as a governor of global gene expression. J Biol Chem. 1994; 269: 15423–15426.
26. Graham FL, Prevec L. Methods in Molecular Biology. Vol 7. Clifton, NJ: The Humana Press Inc; 1991.
27. Abdellatif M, Packer SE, Michael LH, Zhang D, Charng MJ, Schneider MD. A Ras-dependent pathway regulates RNA polymerase II phosphorylation in cardiac myocytes: implications for cardiac hypertrophy. Mol Cell Biol. 1998; 18: 6729–6736.
28. Sano M, Abdellatif M, Oh H, Xie M, Bagella L, Giordano A, Michael LH, DeMayo FJ, Schneider MD. Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat Med. 2002; 8: 1310–1317.[CrossRef][Medline] [Order article via Infotrieve]
29. Lypowy J, Chen IY, Abdellatif M. An alliance between RAS GTPASE-activating protein, filamin C, and G3BP regulates myocyte growth. J Biol Chem. 2005; 280: 25717–25728.
30. Saucedo LJ, Gao X, Chiarelli DA, Li L, Pan D, Edgar BA. Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat Cell Biol. 2003; 5: 566–571.[CrossRef][Medline] [Order article via Infotrieve]
31. Stocker H, Radimerski T, Schindelholz B, Wittwer F, Belawat P, Daram P, Breuer S, Thomas G, Hafen E. Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat Cell Biol. 2003; 5: 559–565.[CrossRef][Medline] [Order article via Infotrieve]
32. Johnatty SE, Dyck JR, Michael LH, Olson EN, Abdellatif M. Identification of genes regulated during mechanical load-induced cardiac hypertrophy. J Mol Cell Cardiol. 2000; 32: 805–815.[CrossRef][Medline] [Order article via Infotrieve]
33. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103: 2257–2261.
34. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005; 65: 6029–6033.
35. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006; 130: 2113–2129.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  M. J. Drummond, E. L. Glynn, C. S. Fry, S. Dhanani, E. Volpi, and B. B. Rasmussen Essential Amino Acids Increase MicroRNA-499, -208b, and -23a and Downregulate Myostatin and Myocyte Enhancer Factor 2C mRNA Expression in Human Skeletal Muscle J. Nutr., December 1, 2009; 139(12): 2279 - 2284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Schroen and S. Heymans MicroRNAs and Beyond: The Heart Reveals Its Treasures Hypertension, December 1, 2009; 54(6): 1189 - 1194. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Divakaran, J. Adrogue, M. Ishiyama, M. L. Entman, S. Haudek, N. Sivasubramanian, and D. L. Mann Adaptive and Maladptive Effects of SMAD3 Signaling in the Adult Heart After Hemodynamic Pressure Overloading Circ Heart Fail, November 1, 2009; 2(6): 633 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. McCarthy, K. A. Esser, C. A. Peterson, and E. E. Dupont-Versteegden Evidence of MyomiR network regulation of {beta}-myosin heavy chain gene expression during skeletal muscle atrophy Physiol Genomics, November 1, 2009; 39(3): 219 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Catalucci, P. Gallo, and G. Condorelli MicroRNAs in Cardiovascular Biology and Heart Disease Circ Cardiovasc Genet, August 1, 2009; 2(4): 402 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Lin, I. Murtaza, K. Wang, J. Jiao, J. Gao, and P.-F. Li miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy PNAS, July 21, 2009; 106(29): 12103 - 12108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Bos, J. A. Towbin, and M. J. Ackerman Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J. Am. Coll. Cardiol., July 14, 2009; 54(3): 201 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kato, L. Arce, and R. Natarajan MicroRNAs and Their Role in Progressive Kidney Diseases Clin. J. Am. Soc. Nephrol., July 1, 2009; 4(7): 1255 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-P. Ren, J. Wu, X. Wang, M. A. Sartor, J. Qian, K. Jones, P. Nicolaou, T. J. Pritchard, and G.-C. Fan MicroRNA-320 Is Involved in the Regulation of Cardiac Ischemia/Reperfusion Injury by Targeting Heat-Shock Protein 20 Circulation, May 5, 2009; 119(17): 2357 - 2366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. G. Barringhaus and P. D. Zamore MicroRNAs: Regulating a Change of Heart Circulation, April 28, 2009; 119(16): 2217 - 2224. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ikeda, A. He, S. W. Kong, J. Lu, R. Bejar, N. Bodyak, K.-H. Lee, Q. Ma, P. M. Kang, T. R. Golub, et al. MicroRNA-1 Negatively Regulates Expression of the Hypertrophy-Associated Calmodulin and Mef2a Genes Mol. Cell. Biol., April 15, 2009; 29(8): 2193 - 2204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rane, M. He, D. Sayed, H. Vashistha, A. Malhotra, J. Sadoshima, D. E. Vatner, S. F. Vatner, and M. Abdellatif Downregulation of MiR-199a Derepresses Hypoxia-Inducible Factor-1{alpha} and Sirtuin 1 and Recapitulates Hypoxia Preconditioning in Cardiac Myocytes Circ. Res., April 10, 2009; 104(7): 879 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Yin, F. N. Salloum, and R. C. Kukreja A Novel Role of MicroRNA in Late Preconditioning: Upregulation of Endothelial Nitric Oxide Synthase and Heat Shock Protein 70 Circ. Res., March 13, 2009; 104(5): 572 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Matkovich, D. J. Van Booven, K. A. Youker, G. Torre-Amione, A. Diwan, W. H. Eschenbacher, L. E. Dorn, M. A. Watson, K. B. Margulies, and G. W. Dorn II Reciprocal Regulation of Myocardial microRNAs and Messenger RNA in Human Cardiomyopathy and Reversal of the microRNA Signature by Biomechanical Support Circulation, March 10, 2009; 119(9): 1263 - 1271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Terentyev, A. E. Belevych, R. Terentyeva, M. M. Martin, G. E. Malana, D. E. Kuhn, M. Abdellatif, D. S. Feldman, T. S. Elton, and S. Gyorke miR-1 Overexpression Enhances Ca2+ Release and Promotes Cardiac Arrhythmogenesis by Targeting PP2A Regulatory Subunit B56{alpha} and Causing CaMKII-Dependent Hyperphosphorylation of RyR2 Circ. Res., February 27, 2009; 104(4): 514 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lu, J. Xiao, H. Lin, Y. Bai, X. Luo, Z. Wang, and B. Yang A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference Nucleic Acids Res., February 1, 2009; 37(3): e24 - e24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. C. Ohlsson Teague, K. H. Van der Hoek, M. B. Van der Hoek, N. Perry, P. Wagaarachchi, S. A. Robertson, C. G. Print, and L. M. Hull MicroRNA-Regulated Pathways Associated with Endometriosis Mol. Endocrinol., February 1, 2009; 23(2): 265 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Duisters, A. J. Tijsen, B. Schroen, J. J. Leenders, V. Lentink, I. van der Made, V. Herias, R. E. van Leeuwen, M. W. Schellings, P. Barenbrug, et al. miR-133 and miR-30 Regulate Connective Tissue Growth Factor: Implications for a Role of MicroRNAs in Myocardial Matrix Remodeling Circ. Res., January 30, 2009; 104(2): 170 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Chen, T. E. Callis, and D.-Z. Wang microRNAs and muscle disorders J. Cell Sci., January 1, 2009; 122(1): 13 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Meder, H. A. Katus, and W. Rottbauer Right into the heart of microRNA-133a Genes & Dev., December 1, 2008; 22(23): 3227 - 3231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Drummond, J. J. McCarthy, C. S. Fry, K. A. Esser, and B. B. Rasmussen Aging differentially affects human skeletal muscle microRNA expression at rest and after an anabolic stimulus of resistance exercise and essential amino acids Am J Physiol Endocrinol Metab, December 1, 2008; 295(6): E1333 - E1340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Divakaran and D. L. Mann The Emerging Role of MicroRNAs in Cardiac Remodeling and Heart Failure Circ. Res., November 7, 2008; 103(10): 1072 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. van Rooij, W. S. Marshall, and E. N. Olson Toward MicroRNA-Based Therapeutics for Heart Disease: The Sense in Antisense Circ. Res., October 24, 2008; 103(9): 919 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. da Costa Martins, M. Bourajjaj, M. Gladka, M. Kortland, R. J. van Oort, Y. M. Pinto, J. D. Molkentin, and L. J. De Windt Conditional Dicer Gene Deletion in the Postnatal Myocardium Provokes Spontaneous Cardiac Remodeling Circulation, October 7, 2008; 118(15): 1567 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. van Rooij, L. B. Sutherland, J. E. Thatcher, J. M. DiMaio, R. H. Naseem, W. S. Marshall, J. A. Hill, and E. N. Olson Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis PNAS, September 2, 2008; 105(35): 13027 - 13032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Thum, D. Catalucci, and J. Bauersachs MicroRNAs: novel regulators in cardiac development and disease Cardiovasc Res, September 1, 2008; 79(4): 562 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Fazi and C. Nervi MicroRNA: basic mechanisms and transcriptional regulatory networks for cell fate determination Cardiovasc Res, September 1, 2008; 79(4): 553 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Yang, Y. Lu, and Z. Wang Control of cardiac excitability by microRNAs Cardiovasc Res, September 1, 2008; 79(4): 571 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sayed, S. Rane, J. Lypowy, M. He, I.-Y. Chen, H. Vashistha, L. Yan, A. Malhotra, D. Vatner, and M. Abdellatif MicroRNA-21 Targets Sprouty2 and Promotes Cellular Outgrowths Mol. Biol. Cell, August 1, 2008; 19(8): 3272 - 3282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. G. Latronico, D. Catalucci, and G. Condorelli MicroRNA and cardiac pathologies Physiol Genomics, August 1, 2008; 34(3): 239 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Luo, H. Lin, Z. Pan, J. Xiao, Y. Zhang, Y. Lu, B. Yang, and Z. Wang Down-regulation of miR-1/miR-133 Contributes to Re-expression of Pacemaker Channel Genes HCN2 and HCN4 in Hypertrophic Heart J. Biol. Chem., July 18, 2008; 283(29): 20045 - 20052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zhang MicroRNomics: a newly emerging approach for disease biology Physiol Genomics, April 1, 2008; 33(2): 139 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-F. Chen, E. P. Murchison, R. Tang, T. E. Callis, M. Tatsuguchi, Z. Deng, M. Rojas, S. M. Hammond, M. D. Schneider, C. H. Selzman, et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure PNAS, February 12, 2008; 105(6): 2111 - 2116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Callis, Z. Deng, J.-F. Chen, and D.-Z. Wang Muscling Through the microRNA World Experimental Biology and Medicine, February 1, 2008; 233(2): 131 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V.G. Latronico, D. Catalucci, and G. Condorelli Emerging Role of MicroRNAs in Cardiovascular Biology Circ. Res., December 7, 2007; 101(12): 1225 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. van Rooij and E. N. Olson microRNAs put their signatures on the heart Physiol Genomics, November 14, 2007; 31(3): 365 - 366. [Full Text] [PDF]
|
|
|
|
|
|
T. Thum, P. Galuppo, C. Wolf, J. Fiedler, S. Kneitz, L. W. van Laake, P. A. Doevendans, C. L. Mummery, J. Borlak, A. Haverich, et al. MicroRNAs in the Human Heart: A Clue to Fetal Gene Reprogramming in Heart Failure Circulation, July 17, 2007; 116(3): 258 - 267. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||